Browse the corpus

The African Critical Illness Outcomes Study (ACIOS) Investigators. The African Critical Illness Outcomes Study (ACIOS): a point prevalence study of critical illness in 22 nations in Africa. Lancet 2025; 405: 715–24—In the appendix of this Article, the names of the ACIOS Investigators have been updated. This correction has been made to the online version as of April 10, 2025.

GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2162–203—In this Article, the Risk category key in figure 7 has been updated with the correct colours. This correction has been made to the online version as of July 18, 2024.

Feikin DR, Melissa MH, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022; 399: 924–44—The methods for the meta-regression section in the appendix of this Article have been corrected as Feb 23, 2023.

GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet 2022; 400: 185–235—Appendices 1 and 2 of this Article have been corrected as of July 19, 2022.

Messacar K, Baker RE, Park SW, Nguyen-Tran H, Cataldi JR, Grenfell B. Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption. Lancet 2022; 400: 1663—In this Comment, the words “winter in” have been added in the second sentence of the first paragraph and the word “to” added to the penultimate sentence of the fourth paragraph. This correction has been made to the online version as of July 18, 2022.

Abbara A, Rao B, Titanji BK, Boum Y, Zumla A. The monkeypox outbreak must amplify hidden voices in the global discourse. Lancet 2022; 400: 23—The title of this Correspondence has been corrected. This correction has been made to the online version as of July 8, 2022.

Lloyd DFA, Pushparajah K, Simpson JM, et al. Three-dimensional visualisation of the fetal heart using prenatal MRI with motion-corrected slice-volume registration: a prospective, single-centre cohort study. Lancet 2019; 393: 1619–27—In this Article, Alexander Schulz's affiliations should have included Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. This correction has been made to the online version as of April 21, 2022.

GBD 2019 Adolescent Mortality Collaborators. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2021; 398: 1593–618—In figure 8 of this Article, the total deaths and proportion in each age group in 1950 were incorrect. These corrections have been made to the online version as of Feb 24, 2022.

Jaffe S. The next steps for US vaccine mandates. Lancet 2022; 399: 425–26—In this World Report, Professor Laurence Tribe's first name was misspelled. This correction has been made to the online version as of Feb 24, 2022.

Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 2022; 399: 625-26—In this Correspondence, the affiliation details of WA Burgers, R Keeton, and C Riou have been corrected to Institute of Infectious Disease and Molecular Medicine (WAB, RK, CR) and Wellcome Centre for Infectious Diseases Research in Africa (CR), University of Cape Town, Observatory, Cape Town, South Africa. These corrections have been made to the online version as of Feb 10, 2021, and the printed version is correct.

Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398: 213–22—In this Article, the name of the funder should have been “Health Institutes of Turkey (TUSEB)”. This correction has been made to the online version as of Jan 27, 2022.

Fleming KA, Horton S, Wilson ML, et al. The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet 2021; published online Oct 6. https://doi.org/10.1016/S0140-6736(21)00673-5—In this Commission, in the section about using governance to make diagnostics more affordable, the sixth sentence of the fourth paragraph should have read “The Treatment Action Group was key in the movement to getting equitable pricing for antiretrovirals for HIV/AIDS and, more recently, has applied similar efforts to diagnostics, such as the Time for $5 campaign for GeneXpert cartridges.” This correction has been made to the online version as of Nov 8, 2021, and will be made to the printed version.

Grange Z, Buelo A, Sullivan C, et al. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. Lancet 2021; published online Oct 28. https://doi.org/10.1016/S0140-6736(21)02316-3—The appendix of this Correspondence has been corrected as of Nov 8, 2021.

Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 398: 843–55—In this Article, in figure 1, “primary analysis” was corrected to “secondary analysis” in reference to the all participants population. In figure 2, the key was incorrect and has now been amended. In figure 3B, a typing error has been corrected in the p value for duration of illness. These corrections have been made to the online version as of Aug 18, 2021, and the printed version is correct.

Carr EJ, Wu M, Harvey R, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet 2021; 398: 1038–41—In this Correspondence, author Matthew P M Graham-Brown's middle initial was incorrect, and reference 15 was incorrect and should have referred to Longlune N et al. Nephrol Dial Transplant 2021. These corrections have been made to the online version as of Aug 17, 2021, and the printed version is correct.

GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019; 393: 1958–72—For this Article, Nayu Ikeda should have been included in the GBD 2017 Diet Collaborators. This correction has been made to the online version as of June 24, 2021.

Kirenga BJ, Byakika-Kibwika P. Excess COVID-19 mortality among critically ill patients in Africa. Lancet 2021; 397: 1860–61—In this Comment, paragraph 3 should have said “It is common in low-income countries to have expensive equipment that is non-functional due to poor maintenance or lack of skilled human resources. It has been estimated that 40% of the medical equipment in many low-income countries is out of service.” This correction has been made to the online version as of June 24, 2021.

The African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet 2021; 397: 1885–94—In this Article, the ACCCOS Investigators list has been updated, and the appendix has been updated. These corrections have been made to the online version as of June 24, 2021.

Patel MG, Dorward J, Yu L-M, Hobbs FDR, Butler CC. Inclusion and diversity in the PRINCIPLE trial. Lancet 2021; 397: 2251–52—The appendix of this Correspondence has been corrected as of June 24, 2021.

Boum Y, Bebell LM, Zoung-Kanyi Bisseck A-C. Africa needs local solutions to face the COVID-19 pandemic. Lancet 2021; 397: 1238–40—This Comment should have been published with the copyright line “Published by Elsevier Ltd”. This correction has been made to the online version as of June 17, 2021.

GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet 2021; 397: 2337–60—In this Article, the GBD 2019 Tobacco Collaborators list and accompanying affiliations have been updated. These corrections have been made to the online version as of June 2, 2021, and the printed version is correct.

Anderson M, Pitchforth E, Asaria M, et al. LSE–Lancet Commission on the future of the NHS: re-laying the foundations for an equitable and efficient health and care service after COVID-19. Lancet 2021; 397: 1915–78—In this Commission, the third sentence in the Financial and political context section should read “Efforts to support individuals and businesses—for example, through furloughing, grants, and loans—have substantially increased government borrowing, which reached approximately £350 billion in 2020”. This correction has been made to the online version as of May 20, 2021 and the printed version is correct.

Hyde R. Controversy surrounds Merkel's new lockdown powers. Lancet 2021; 397: 1610—In this World Report, the Social Democratic Party was incorrectly referred to as the opposition party. This correction has been made to the online version as of May 20, 2021.

The Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397: 1625–36—For this Article, The Blood Pressure Lowering Treatment Trialists' Collaboration group list has been updated. This correction has been made to the online version as of May 20, 2021.

Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 2021; published online May 12. https://doi.org/10.1016/S0140-6736(21)01115-6—In this Correspondence, the affiliation details for RHS, AS, MG, XL, and MDS should have been the Department of Paediatrics at the University of Oxford. MDS is also affiliated with the NIHR Oxford Biomedical Research Centre at the Oxford University Hospitals NHS Foundation Trust. The appendix has also been corrected. These corrections have been made to the online version as of May 18, 2021, and will be made to the print version.

Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet 2021; 397: 1603–05—In this Comment, the conflict of interest statement for David Fisman has been corrected according to what was declared on his ICMJE form to read: “DF is funded by the Canadian Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360), received consulting fees as a legal expert for Elementary Teachers Federation of Ontario in August and September, 2020, related to COVID-19 transmission in schools, including the importance of ventilation and masks for kids as source control, and currently serves as a legal expert for the Ontario Nurses Association on their challenge to Ontario Directive 5, which restricts access to N95 masks for health-care workers except during performance of aerosol generating medical procedures.” This correction has been made to the online version as of May 13, 2021.

Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021; 397: 1375–86—In this Article, N Vora should not have been included in the SANAD II collaborators list. This correction has been made to the online version as of May 13, 2021.

Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021; 397: 1363–74—In this Article, N Vora should not have been included in the SANAD II collaborators list. This correction has been made to the online version as of May 13, 2021.

Chauvin L. Peruvian COVID-19 vaccine scandal spreads. Lancet 2021; 397: 783—This World Report incorrectly stated that clinical trials had been halted at Cayetano Heredia University. The National Institute of Health suspended the unit at Cayetano Heredia University doing the Sinopharm trial, pending an investigation. It did not suspend other trials. This correction has been made to the online version as of May 13, 2021.

The SIREN Study Group. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021; 397: 1459–69—For this Article, Mariyam Mirfenderesky and Thushan De Silva should have been included in the SIREN Study Group, and author EJM Monk's initials have been corrected. These corrections have been made to the online version as of May 6, 2021.

Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet 2021; 397: 1711–24—In figure 4 of this Article, the written hazard ratios and 95% CIs were incorrect and have been amended. These corrections have been made to the online version as of May 6, 2021, and the printed version is correct.

Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021; 397: 1375–86—Appendices 3 and 4 of this Article have been corrected as of April 22, 2021.

Bojorquez I, Cabieses B, Arósquipa C, et al. Migration and health in Latin America during the COVID-19 pandemic and beyond. Lancet 2021; 397: 1243–45—In this Comment, the date of the Ibero-American Summit has been corrected to April 21, 2021. This correction has been made to the online version as of April 15, 2021.

Commissioners of the Lancet COVID-19 Commission, Task Force Chairs and members of the Lancet COVID-19, Commission, Commission Secretariat and Staff of the Lancet COVID-19 Commission. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. Lancet 2021; 397: 947–50—In this Comment, the role and affiliation for George Laryea-Adjei has been corrected to, UNICEF Regional Director for South Asia, Ghana. This correction has been made to the online version as of March 11, 2021, and the printed version is correct.

GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet 2021; 397: 387–97—In figure 1 of this Article, the 1337 patients from 263 hospitals who had surgery and were included in the analysis should have been reported as having “gastric cancer”. Additionally, members of the protocol development group should have been included in the GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery study group list, and the appendix has been updated. These corrections have been made to the online version as of March 4, 2021.

Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397: 881–91—In this Article, in figure 3, some of the datapoints on the graphs and the key on the left panel have both been corrected. These corrections have been made to the online version as of March 4, 2021, and the printed version is correct.

Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020; 395: 117–22—In this Article, Bernardo Bonanni's affiliation should have been “Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy”. This correction has been made to the online version as of Feb 25, 2021.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397: 671–81—In this Article, the funder list has been updated by removing one that was incorrectly listed; in figure 2, the number at risk at the day 20 timepoint has been corrected to 15 117; in figure 3B, the number of male participants labelled on the graph has been corrected to 46; and in the legend of figure 3, the following sentence has been added for clarity: “Four participants are not included in the subgroup analysis by age because of missing date of birth on the case report form for this analysis”. These corrections have been made to the online version as of Feb 18, 2021, and the printed version is correct.

Li X, Mukandavire C, Cucunubà ZM, et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet 2021; 397: 398–408—In appendix 2, the table legends for appendix 3 p 1 (d–f) and p 2 (d–f) should have been for under-5s by calendar view, and the table legends for appendix 3 p 1 (g–i) and p 2 (g–i) should have been for all ages by cohort view. The titles of the tables have also been corrected. These corrections have been made as of Feb 18, 2021.

Zarocostas J. WHO team begins COVID-19 origin investigation. Lancet 2021; 397: 459—In this World Report, the description of the investigation team was incorrect. It should have read: “…also five WHO experts, two representatives from the Food and Agriculture Organization, and two from the World Organisation for Animal Health (OIE).” This correction has been made to the online version as of Feb 16, 2021.

Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111—In this Article, Keertan Dheda's affiliation with the London School of Hygiene & Tropical Medicine has been added, and appendix 1 has been corrected. This correction has been made to the printed version, and to the online versions as of Jan 7, 2021.

Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396: 887–97—In this Article, in the third paragraph of the Results section, the geometric mean titre of IgGs in participants receiving Gam-COVID-Vac should have read 1345, and the geometric mean titres of IgG on day 28 should have read 5382. In tables S3 and S4 of the appendix, the baseline titres for IgG on day 0 should have been 12.5. In table S5 of the appendix, the baseline titres of NtAb should have been 1.250. Author Amir I Tukhvatulin's name was misspelled in the author byline and in the affiliations section. These corrections have been made to the online version as of Jan 7, 2021.

Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020; 396: 1979–93—In the Summary of this Article, the third sentence of the Background section should have read “We have reported the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), in young adults…”, and in the fifth paragraph of the Introduction, the third sentence should have read “ChAdOx1 nCoV-19 (AZD1222) is a replication-defective chimpanzee adenovirus-vectored vaccine…”. In the Procedures section, the location of Symbiosis should have been “Stirling, UK”, and the appendix has been updated. These corrections have been made to the online version as of Dec 17, 2020, and the printed version is correct.

Cieza A, Causey K, Kamenov K, Hanson SW, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 2006–17—In this Article, in the Findings section of the Summary and in the Results and Discussion sections, low back pain has been corrected to the most prevalent condition in 160 of the 204 countries analysed. In the Findings section of the Summary, the prevalence of musculoskeletal disorders has been corrected to 1·71 billion people (1·63–1·80). In the Research in context panel and the Discussion section, the estimated number of people with conditions that could benefit from rehabilitation has been corrected to 2·41 billion. These corrections have been made to the online version as of Dec 4, 2020.

Ewing A. COVID-19—a very visible pandemic. Lancet 2020; 396: e18—In this Correspondence, the third and final sentences of the fourth paragraph should have said, “The death rate is much higher in countries (1) that delayed lockdown, (2) where posters calling for an approach like Sweden's arguably led to people in these countries (eg, Brazil and the USA) attempting to follow the Swedish approach to the pandemic, and (3) that were released from lockdown early by their government”, and “The attempt to reach herd immunity, and the public promotion of herd immunity to others, has cost many lives”, respectively. These corrections have been made to the online version as of Aug 10, 2020.